Search
LX6171
go.drugbank.com/drugs/DB05180InvestigationalLX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia
Cefotetan
go.drugbank.com/drugs/DB01330ApprovedInvestigationalThe drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.
Oleoyl-estrone
go.drugbank.com/drugs/DB04870InvestigationalBody protein loss is an unpleasant effect of fat loss by the restriction of calories, and studies show that this drug appears to avoid this effect. … It has been shown in animal studies to promote the loss of body fat while maintaining body protein storage, maintaining nitrogen balance.
Olaratumab
go.drugbank.com/drugs/DB06043ApprovedInvestigationalOlaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.
Amcipatricin
go.drugbank.com/drugs/DB12333InvestigationalAmcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone
Netarsudil
go.drugbank.com/drugs/DB13931ApprovedInvestigationalact as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many … rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to
Benoxaprofen
go.drugbank.com/drugs/DB04812ApprovedWithdrawnThe holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalPhosphoaminophosphonic acid guanylate ester
go.drugbank.com/drugs/DB02082ExperimentalA non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+.
Synonyms: Gpp(NH)pKDT-3594
go.drugbank.com/drugs/DB17085InvestigationalKDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.
Rauwolfia serpentina root
go.drugbank.com/drugs/DB09363InvestigationalThis product was approved prior to Jan 1, 1982, but since, has been discontinued due to its propensity for leading to depression [L1616, L1630]. … Rauwolfia serpentina is also commonly referred to as _Sarpaghanda_ [A32097].